36 382

Cited 40 times in

Expression of excision repair cross-complementation group 1 protein predicts poor outcome in patients with small cell lung cancer.

Lee, HW; Han, JH; Kim, JH; Lee, MH; Jeong, SH; Kang, SY; Choi, JH; Oh, YT; Park, KJ; Hwang, SC; Sheen, SS; Lim, HY
Lung cancer (Amsterdam, Netherlands), 59(1):95-104, 2008
Journal Title
Lung cancer (Amsterdam, Netherlands)
BACKGROUND: Alterations in apoptosis-related proteins and DNA damage repair proteins are associated with resistance to chemotherapy or radiotherapy, which is the most important cause of treatment failure in small cell lung cancer (SCLC).

PATIENTS AND METHODS: Pretreatment tumor biopsy specimens from 77 patients with SCLC (limited stage: 40, extensive stage: 37) were analyzed for p53, bcl-2, bax and ERCC1 expression by immunohistochemistry. All patients were treated with platinum-based doublets. The most commonly used regimen was etoposide/cisplatin (50 patients). In patients with limited stage SCLC, thoracic irradiation was performed either concurrently with chemotherapy or sequentially.

RESULTS: High expression of p53, bcl-2, bax and ERCC1 was observed in 40 (52%), 72 (94%), 38 (49%) and 13 (17%) patients, respectively. High expression of ERCC1 was associated with poor OS (1-year, 23% vs. 53%; p=0.026). When grouped according to stage, a significant correlation between high expression of ERCC1 and poor outcome was observed only in patients with limited stage SCLC (p=0.017). High expression of p53, bcl-2 and bax was not correlated with patient outcome. Multivariate analysis showed that extensive stage (p=0.006) and male gender (p=0.009) were independent predictors of poor OS, while high expression of ERCC1 failed to reach statistical significance despite a trend (p=0.057). In limited stage patients, high expression of ERCC1 was an independent prognostic factor for poor OS (p=0.046), along with male gender (p=0.033).

CONCLUSIONS: High expression of ERCC1 protein may be a useful predictor of poor outcome in SCLC patients treated with chemotherapy with or without radiotherapy, especially in limited stage SCLC.
MeSH terms
AdultAgedCarcinoma, Small Cell/chemistry*Carcinoma, Small Cell/mortalityDNA-Binding Proteins/analysis*Endonucleases/analysis*FemaleHumansImmunohistochemistryLung Neoplasms/chemistry*Lung Neoplasms/mortalityMaleMiddle AgedProto-Oncogene Proteins c-bcl-2/analysisTumor Suppressor Protein p53/analysisbcl-2-Associated X Protein/analysis
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Hematology-Oncology
Journal Papers > School of Medicine / Graduate School of Medicine > Pathology
Journal Papers > School of Medicine / Graduate School of Medicine > Radiation Oncology
Journal Papers > School of Medicine / Graduate School of Medicine > Pulmonary & Critical Care Medicine
Journal Papers > School of Medicine / Graduate School of Medicine > Medical Science
AJOU Authors
이, 현우한, 재호김, 장희정, 성현강, 석윤최, 진혁오, 영택박, 광주황, 성철신, 승수
Full Text Link
RIS (EndNote)
XLS (Excel)


해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.